Stock Performance and Market Context
On 20 May 2026, Novartis India Ltd’s stock surged by 5.45% to close at Rs 1,274.85, just 0.01% shy of its 52-week high of Rs 1,275. This performance notably outpaced the Sensex, which declined by 0.29% on the same day, and also outperformed its sector by 2.77%. The stock has demonstrated strong momentum, gaining for two consecutive days with a cumulative return of 5.76% during this period. Intraday, the share price touched a high of Rs 1,250.20, reflecting a 3.41% increase from the previous close.
Novartis India is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a robust bullish trend. The overall technical trend is classified as bullish, having shifted from a mildly bullish stance on 6 May 2026 when the price was at Rs 1,050.70.
Long-Term Returns and Relative Strength
The stock’s long-term performance has been impressive relative to the broader market. Over the past year, Novartis India Ltd has delivered a return of 41.23%, significantly outperforming the Sensex’s negative return of 7.64%. Year-to-date, the stock has surged by 63.65%, while the Sensex has declined by 12.01%. Over three and five years, the stock has appreciated by 76.11% and 103.54% respectively, compared to Sensex gains of 21.48% and 51.29%. Even over a decade, Novartis India Ltd has posted an 80.45% gain, though this trails the Sensex’s 196.37% growth over the same period.
Valuation Metrics as of 20 May 2026
At the current price level, the stock trades at a price-to-earnings (P/E) ratio of 32 times on a trailing twelve months (TTM) basis. The price-to-book value (P/BV) stands at 3.65 times, while the enterprise value to EBITDA (EV/EBITDA) ratio is 24.64 times. Other valuation multiples include EV/EBIT at 25.16 times and EV/Sales at 6.54 times, with EV/Capital Employed at 15.12 times. The PEG ratio is not available.
Dividend metrics indicate a yield of 2.07%, with the latest dividend declared at Rs 25 per share. The dividend payout ratio is 61.15%, reflecting a consistent return of capital to shareholders. The ex-dividend date was 23 July 2025.
Technical Analysis and Key Levels
Technical indicators present a predominantly bullish outlook. Weekly and monthly MACD readings are bullish, supported by bullish Bollinger Bands and moving averages. The KST indicator is bullish weekly and mildly bullish monthly. However, the Relative Strength Index (RSI) remains bearish on both weekly and monthly timeframes, suggesting some caution in momentum strength.
Key support levels include the 52-week low of Rs 750, which also serves as immediate support. Resistance levels are identified at Rs 1,089.43 (20-day moving average area), Rs 916.05 (100-day moving average), and Rs 897.65 (200-day moving average). The 52-week high of Rs 1,275 represents a major resistance point that the stock has now reached.
Quality Assessment and Financial Strength
Novartis India Ltd is classified as an average quality company based on long-term financial performance. The management risk is rated average, while growth prospects are considered good. The company boasts an excellent capital structure, characterised by negligible debt levels and a net cash position.
Key quality indicators include a five-year EBIT growth of 44.49%, an average EBIT to interest coverage ratio of 48.35 times, and an average debt to EBITDA ratio of 0.42, indicating minimal leverage. The company maintains a strong return on capital employed (ROCE) averaging 36.34%, although return on equity (ROE) is relatively weak at 11.13%. Sales growth over five years has been slightly negative at -1.46%, but the company’s consistent profitability and strong balance sheet underpin its market valuation.
Additional quality factors include zero promoter share pledging, low institutional holdings at 0.71%, and a consistent dividend payer status. The tax ratio stands at 28.14%, and sales to capital employed ratio is 0.48x.
Short-Term Financial Trends
Recent quarterly data shows mixed trends. The company reported its highest cash and cash equivalents at ₹667.70 crores and a peak debtors turnover ratio of 9.56 times. Net sales for the quarter reached a high of ₹90.55 crores. However, some profitability metrics have declined, with quarterly PAT falling by 13.8% to ₹25.25 crores and operating profit to net sales ratio dropping to 22.77%. The profit before tax excluding other income also decreased to ₹20.13 crores. Non-operating income accounted for 33.21% of profit before tax, indicating a significant contribution from non-core activities.
Volume and Delivery Trends
Delivery volumes have shown notable activity, with a 69.62% increase in delivery volume on 20 May 2026 compared to the five-day average. The stock’s average delivery volume over the trailing month was 22.49 thousand shares, representing 57.81% of total volume, up from zero in the previous month’s average, indicating renewed trading interest.
Market Capitalisation and Mojo Rating
Novartis India Ltd is classified as a small-cap company. The MarketsMOJO score stands at 50.0, with a current Mojo Grade of Hold, upgraded from Sell on 11 May 2026. This reflects a reassessment of the stock’s market position and performance metrics.
Summary
Novartis India Ltd’s stock reaching its all-time high of Rs 1,275 on 20 May 2026 marks a significant achievement, underscored by strong price momentum, robust long-term returns, and a solid technical outlook. The company’s valuation multiples reflect a premium consistent with its sector and growth profile, while its quality assessment highlights a stable financial foundation with minimal debt and consistent dividend payments. Despite some short-term softness in profitability metrics, the overall market response has been positive, as evidenced by the stock’s outperformance relative to the Sensex and its sector peers.
